HC Wainwright Brokers Cut Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Research analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for G1 Therapeutics in a note issued to investors on Thursday, May 2nd. HC Wainwright analyst E. White now anticipates that the company will post earnings of $0.72 per share for the year, down from their previous forecast of $0.76. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.64) per share.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. The company had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. During the same quarter in the prior year, the company posted ($0.53) EPS.

GTHX has been the subject of a number of other reports. Wedbush reiterated an “outperform” rating and set a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Stock Up 1.1 %

Shares of G1 Therapeutics stock opened at $4.49 on Friday. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a quick ratio of 3.45, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. The company’s 50 day moving average is $3.94 and its 200 day moving average is $3.09. The company has a market cap of $234.74 million, a price-to-earnings ratio of -7.24 and a beta of 1.71.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Raymond James & Associates raised its position in shares of G1 Therapeutics by 16.9% during the 3rd quarter. Raymond James & Associates now owns 925,776 shares of the company’s stock valued at $1,333,000 after purchasing an additional 133,662 shares during the period. abrdn plc purchased a new position in shares of G1 Therapeutics in the fourth quarter valued at about $1,293,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after acquiring an additional 82,879 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of G1 Therapeutics during the third quarter worth about $189,000. Finally, FinTrust Capital Advisors LLC grew its position in shares of G1 Therapeutics by 154,946.2% during the fourth quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock worth $307,000 after purchasing an additional 100,715 shares in the last quarter. 24.21% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Rajesh Malik sold 28,600 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 8.23% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.